Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US medtech, biotech companies still concerned with revised patent reform bill - update

This article was originally published in RAJ Devices

Executive Summary

Legislation to reform US patent law has been revised and reintroduced in the House of Representatives and the Senate1,2. The Patent Reform Act of 2009 continues to draw stiff opposition from the medtech, biotech and pharmaceutical industry associations, despite attempts by lawmakers to address their concerns and make improvements to the previous version of the act that was introduced in the previous Congress.

You may also be interested in...



High Expectations From EU’s ‘Neutral’ Hub On Real-World Evidence

The Netherlands-based GetReal Institute builds on seven years of multi-stakeholder collaboration to promote greater understanding of real-world evidence.

How COVID-19 Is Driving RWE Uptake In Clinical Trials

With the COVID-19 pandemic exacerbating the challenges of recruiting patients for studies targeting catastrophic diseases and rare cancers, regulators are becoming more receptive to new ways of using real-world evidence in clinical trials.

EMA Explains Procedure For Parallel Review Of Drugs For EU And Non-EU Markets

Companies can get the European Medicines Agency’s scientific opinion for their products’ use in EU and non-EU countries at about the same time.

UsernamePublicRestriction

Register

SC095219

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel